Skip to content
Triangle logo TriangleGet started
← Study library

NCT01822496 · CITED IN SOURCE DOCUMENTS

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2019-08-05

This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Percentage of Patients With Complete or Partial Response

→

outcome · POSTED

Number of Patients With Grade 3-5 Adverse Events

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Local-regional Progression-free Survival

→

outcome · POSTED

Distant Progression-free Survival

→

outcome · POSTED

Correlation Between Clinical Outcomes and Tumor Molecular Aberrations

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC * Unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm N2 or N3 disease; patients may have invasive mediastinal staging by mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery (VATS) * Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are eligible * Patients must have measurable disease, i.e., lesions that can be accurately measured in at least 1 dimension (longest dimension in the plane of measurement is to be recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan slice thickness no greater than 5 mm) * Patients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy * If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible * The institution's pre-enrollment biomarker screening at a Clinical Laboratory Improvement Amendments (CLIA) certified lab documents presence of known "sensitive" mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement; either the primary tumor or the metastatic lymph node tissue may be used for testing of mutations * The institution's pre-enrollment biomarker screening at a CLIA certified lab documents absence of T790M mutation in the EGFR TK domain * Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup: * History/physical examination, including recording of pulse, blood pressure (BP), weight, and body surface area, within 45 days prior to registration * Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to mid-thighs) within 30 days prior to registration; PET/CT must be negative for distant metastasis * CT scan with contrast of the chest and upper abdomen to include liver and adrenals (unless medically contraindicated) within 30 days prior to registration * Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with contrast, if MRI medically contraindicated) within 30 days prior to registration * Zubrod performance status 0-1 within 14 days prior to registration * Absolute neutrophil count (ANC) \>= 1,000 cells/mm\^3 * Platelets \>= 100,000 cells/mm\^3 * Hemoglobin \>= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * Serum creatinine \< 1.5 mg/dL or calculated creatinine clearance \>= 50 ml/min (by Cockcroft-Gault formula) within 14 days prior to registration * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN) within 14 days prior to registration * Bilirubin within normal institutional limits within 14 days prior to registration * Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential * Patient must provide study specific informed consent prior to study entry, including consent for mandatory screening of tissue Exclusion Criteria: * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) * Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * Atelectasis of the entire lung * Contralateral hilar node involvement * Exudative, bloody, or cytologically malignant effusions * Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months * Transmural myocardial infarction within the last 6 months * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Prior allergic reaction to the study drug(s) involved in this protocol
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
    intervention Names
    1. Radiation: Radiation Therapy
    2. Drug: Carboplatin
    3. Drug: Cisplatin
    4. Drug: Erlotinib
    5. Drug: Etoposide
    6. Drug: Paclitaxel
    label
    EGFR: Erlotinib
    type
    EXPERIMENTAL
  2. description
    Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
    intervention Names
    1. Radiation: Radiation Therapy
    2. Drug: Carboplatin
    3. Drug: Cisplatin
    4. Drug: Etoposide
    5. Drug: Paclitaxel
    label
    EGFR: No Erlotinib
    type
    ACTIVE_COMPARATOR
  3. description
    Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
    intervention Names
    1. Radiation: Radiation Therapy
    2. Drug: Carboplatin
    3. Drug: Cisplatin
    4. Drug: Crizotinib
    5. Drug: Etoposide
    6. Drug: Paclitaxel
    label
    ALK: Crizotinib
    type
    EXPERIMENTAL
  4. description
    Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
    intervention Names
    1. Radiation: Radiation Therapy
    2. Drug: Carboplatin
    3. Drug: Cisplatin
    4. Drug: Etoposide
    5. Drug: Paclitaxel
    label
    ALK: No Crizotinib
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. ALK: Crizotinib
    2. ALK: No Crizotinib
    3. EGFR: Erlotinib
    4. EGFR: No Erlotinib
    description
    30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
    name
    Radiation Therapy
    other Names
    1. 3-dimensional conformal radiation therapy
    2. 3-dimensional radiation therapy
    3. 3D CONFORMAL RADIATION THERAPY
    4. 3D CRT
    5. 3D-CRT
    6. Conformal Therapy
    7. Radiation Conformal Therapy
    8. IMRT
    9. Intensity-modulated radiation therapy
    type
    RADIATION
  2. arm Group Labels
    1. ALK: Crizotinib
    2. ALK: No Crizotinib
    3. EGFR: Erlotinib
    4. EGFR: No Erlotinib
    description
    Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable. Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22.
    name
    Carboplatin
    other Names
    1. Blastocarb
    2. Carboplat
    3. Carboplatin Hexal
    4. Carboplatino
    5. Carbosin
    6. Carbosol
    7. Carbotec
    8. CBDCA
    9. Displata
    10. Ercar
    11. JM-8
    12. Nealorin
    type
    DRUG
  3. arm Group Labels
    1. ALK: Crizotinib
    2. ALK: No Crizotinib
    3. EGFR: Erlotinib
    4. EGFR: No Erlotinib
    description
    50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
    name
    Cisplatin
    other Names
    1. Abiplatin
    2. Blastolem
    3. Briplatin
    4. CDDP
    5. Cis-diammine-dichloroplatinum
    6. Cis-diamminedichloridoplatinum
    7. Cis-diamminedichloro Platinum (II)
    8. Cis-diamminedichloroplatinum
    9. Cis-dichloroammine Platinum (II)
    10. Cis-platinous Diamine Dichloride
    11. Cis-platinum
    12. Cis-platinum II
    type
    DRUG
  4. arm Group Labels
    1. ALK: Crizotinib
    description
    250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
    name
    Crizotinib
    other Names
    1. MET Tyrosine Kinase Inhibitor PF-02341066
    2. PF-02341066
    3. PF-2341066
    4. Xalkori
    type
    DRUG
  5. arm Group Labels
    1. EGFR: Erlotinib
    description
    150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
    name
    Erlotinib
    other Names
    1. Cp-358,774
    2. Erlotinib Hydrochloride
    3. OSI-774
    4. Tarceva
    type
    DRUG
  6. arm Group Labels
    1. ALK: Crizotinib
    2. ALK: No Crizotinib
    3. EGFR: Erlotinib
    4. EGFR: No Erlotinib
    description
    50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
    name
    Etoposide
    other Names
    1. Demethyl Epipodophyllotoxin Ethylidine Glucoside
    2. EPEG
    3. Lastet
    4. Toposar
    5. Vepesid
    6. VP 16-213
    7. VP-16
    8. VP-16-213
    type
    DRUG
  7. arm Group Labels
    1. ALK: Crizotinib
    2. ALK: No Crizotinib
    3. EGFR: Erlotinib
    4. EGFR: No Erlotinib
    description
    Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable. Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
    name
    Paclitaxel
    other Names
    1. Anzatax
    2. Asotax
    3. Bristaxol
    4. Praxel
    5. Taxol
    6. Taxol Konzentrat
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
59
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions at any location. Progression-free survival time is measured from the date of randomization to the date of first progression, death, or last known follow-up (censored). No statistical testing was done due to early study termination.
    measure
    Progression-free Survival
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
secondary Outcomes
  1. description
    Per the RECIST guideline v1.1 complete response is defined as the disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. No statistical testing was done due to early study termination.
    measure
    Percentage of Patients With Complete or Partial Response
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
  2. description
    Adverse events (AE) are graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.
    measure
    Number of Patients With Grade 3-5 Adverse Events
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
  3. description
    Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.
    measure
    Overall Survival
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
  4. description
    Progression is defined using the RECIST guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new regional lesions. Local progression is defined as progression within the planning target volume (PTV). Regional progression is defined as progression outside of the PTV but within the same lobe of the lung as the primary tumor or in regional lymph nodes as defined by the American Joint Committee on Cancer (AJCC) 7th edition nodal stations. Local-regional progression-free survival time is measured from the date of randomization to the date of first local-regional progression, death, or last known follow-up (censored). Local-regional progression-free survival rates are estimated using the Kaplan-Meier method. No testing was done due to early study termination.
    measure
    Local-regional Progression-free Survival
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
  5. description
    Distant progression is defined as the first occurrence of distant metastasis. Distant progression-free survival time is measured from the date of randomization to the date of first distant progression, death, or last known follow-up (censored). Distant progression-free survival rates are estimated using the Kaplan-Meier method. No testing was done due to early study termination.
    measure
    Distant Progression-free Survival
    time Frame
    From randomization to study termination. Maximum follow-up was 39.0 months
  6. measure
    Correlation Between Clinical Outcomes and Tumor Molecular Aberrations
    time Frame
    Baseline
Full study description
brief Summary
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.
detailed Description
PRIMARY OBJECTIVES: I. To assess whether patients with unresectable local-regionally advanced non-small cell lung cancer (NSCLC) treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone. SECONDARY OBJECTIVES: I. To evaluate response rate. II. To assess toxicity. III. To assess overall survival. IV. To correlate clinical outcomes with tumor molecular aberrations identified from deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available. OUTLINE: Eligible patients are assigned to one of two cohorts based on pre-enrollment screening by the enrolling institution for two biomarkers: EGFR TK mutation and EML4-ALK fusion arrangement. Within each cohort, patients are randomized to either an experimental or control arm, resulting in a total of four treatment arms overall. Patients with both the EGFR mutation and ALK arrangement are placed in the ALK Cohort. Planned Sample Size: 156 for the EGFR mutation cohort and 78 for the ALK translocation cohort After completion of study treatment, patients are followed at 1 and 2 months, 4-6 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-4d2c86305bceb55576fe
      requested nct id
      NCT01822496
      primary nct id
      NCT01822496
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      payload sha256
      566d71b0a50ff1fb44bdd82db8b00cbad6aeafd7eb681d9f81d59ed436b09be9
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-4d2c86305bceb55576fe
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01822496
      occurrences
      1. context exact
        dality therapy in patients with <em class="gene-name">EGFR</em> variants or <em class="gene-name">ALK</em> translocations (RTOG-1306 [<a href="/clinicaltrials/NCT01822496">NCT01822496</a>]; 11-464 [<a href="/clinicaltrials/NCT01553942">NCT01553942</a>]) (under clinical evaluation).</li><li> Adaptive radiation therapy using posit
        end
        385064
        exact text
        NCT01822496
        start
        385053
      2. context exact
        y in patients with <em class="gene-name">EGFR</em> variants or <em class="gene-name">ALK</em> translocations (RTOG-1306 [<a href="/clinicaltrials/NCT01822496">NCT01822496</a>]; 11-464 [<a href="/clinicaltrials/NCT01553942">NCT01553942</a>]) (under clinical evaluation).</li><li> Adaptive radiation therapy using positron emission
        end
        385077
        exact text
        NCT01822496
        start
        385066
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.782436+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
      source title
      Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 15, 2025
        datetime
        2025-05-15T12:00:00Z
        display
        May 15, 2025

    Preserved source evidence · Not medical advice